DIADEMA PARTNERS LP — 13F Holdings & Portfolio
CIK 2026172 · latest 13F-HR filed 2026-05-15
DIADEMA PARTNERS LP manages $587.7M in 13F-reported U.S. long-equity assets across 144 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are VRTX (7.07%), LQDA (4.25%), UTHR (4.06%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 44 new positions, exited 31, added to 16, and trimmed 23.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$587.7M
Long-equity book
144
Distinct positions
2026-03-31
Filed 2026-05-15
+44 / −31 / ↑16 / ↓23
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- UNITED THERAPEUTICS CORP DEL$11.3M +232.3%
- COGENT BIOSCIENCES INC$7.7M +165.3%
- VIKING THERAPEUTICS INC$5.2M +44.2%
- REVOLUTION MEDICINES INC$4.9M +166.7%
- IMMUNOCORE HLDGS PLC$3.4M +138.7%
Top Trims
- TERNS PHARMACEUTICALS INC-$4.4M -31.4%
- CORCEPT THERAPEUTICS INC-$3.0M -88.1%
- VERTEX PHARMACEUTICALS INC-$2.8M -62.2%
- BIOAGE LABS INC-$2.5M -70.7%
- CAPRICOR THERAPEUTICS INC-$2.2M -47.5%
New Positions
- BRIDGEBIO PHARMA INC$18.6M
- JAZZ PHARMACEUTICALS PLC$10.4M
- KODIAK SCIENCES INC$7.4M
- INCYTE CORP$7.3M
- ABBVIE INC$5.2M
Exited Positions
- REGENERON PHARMACEUTICALS$8.0M
- ANI PHARMACEUTICALS INC$4.2M
- IRONWOOD PHARMACEUTICALS INC$2.3M
- CENTESSA PHARMACEUTICALS PLC$2.3M
- ALNYLAM PHARMACEUTICALS INC$2.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | VERTEX PHARMACEUTICALS INC Call | VRTX | 92532F100 | $41.6M | 7.07% | 93,100 | SH |
| 2 | LIQUIDIA CORPORATION Call | LQDA | 53635D202 | $25.0M | 4.25% | 662,100 | SH |
| 3 | UNITED THERAPEUTICS CORP DEL Call | UTHR | 91307C102 | $23.8M | 4.06% | 40,200 | SH |
| 4 | VIKING THERAPEUTICS INC Call | VKTX | 92686J106 | $21.5M | 3.65% | 659,200 | SH |
| 5 | CAPRICOR THERAPEUTICS INC Put | CAPR | 14070B309 | $19.0M | 3.22% | 623,400 | SH |
| 6 | APOGEE THERAPEUTICS INC Call | APGE | 03770N101 | $18.7M | 3.19% | 222,500 | SH |
| 7 | BRIDGEBIO PHARMA INC | BBIO | 10806XAJ1 | $18.6M | 3.16% | 250,000 | SH |
| 8 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $17.1M | 2.91% | 525,181 | SH |
| 9 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $16.2M | 2.75% | 27,303 | SH |
| 10 | CYTOKINETICS INC Put | CYTK | 23282W605 | $13.2M | 2.24% | 200,000 | SH |
| 11 | JOHNSON & JOHNSON | JNJ | 478160104 | $13.1M | 2.24% | 53,771 | SH |
| 12 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $12.4M | 2.11% | 322,764 | SH |
| 13 | REVOLUTION MEDICINES INC Put | RVMD | 76155X100 | $12.2M | 2.08% | 125,500 | SH |
| 14 | MERCK & CO INC Put | MRK | 58933Y105 | $12.0M | 2.05% | 100,000 | SH |
| 15 | UNITED THERAPEUTICS CORP DEL Put | UTHR | 91307C102 | $11.9M | 2.02% | 20,000 | SH |
| 16 | ABIVAX SA Put | ABVX | 00370M103 | $11.1M | 1.89% | 100,000 | SH |
| 17 | ABIVAX SA Call | ABVX | 00370M103 | $11.1M | 1.89% | 100,000 | SH |
| 18 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $10.4M | 1.76% | 54,755 | SH |
| 19 | CAPRICOR THERAPEUTICS INC Call | CAPR | 14070B309 | $10.0M | 1.70% | 329,300 | SH |
| 20 | INCYTE CORP Put | INCY | 45337C102 | $9.9M | 1.69% | 105,400 | SH |
| 21 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $9.6M | 1.63% | 181,752 | SH |
| 22 | KODIAK SCIENCES INC Put | KOD | 50015M109 | $9.4M | 1.60% | 246,900 | SH |
| 23 | ROIVANT SCIENCES LTD Put | ROIV | G76279101 | $9.3M | 1.58% | 335,800 | SH |
| 24 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $8.4M | 1.42% | 148,229 | SH |
| 25 | ABIVAX SA | ABVX | 00370M103 | $8.2M | 1.40% | 75,944 | SH |
| 26 | MODERNA INC Put | MRNA | 60770K107 | $8.1M | 1.38% | 159,400 | SH |
| 27 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $7.9M | 1.34% | 80,872 | SH |
| 28 | KODIAK SCIENCES INC | KOD | 50015M109 | $7.4M | 1.25% | 192,962 | SH |
| 29 | INCYTE CORP | INCY | 45337C102 | $7.3M | 1.25% | 78,029 | SH |
| 30 | TG THERAPEUTICS INC | TGTX | 88322Q108 | $6.9M | 1.17% | 206,928 | SH |
| 31 | EDGEWISE THERAPEUTICS INC Call | EWTX | 28036F105 | $6.7M | 1.14% | 212,500 | SH |
| 32 | CORCEPT THERAPEUTICS INC Call | CORT | 218352102 | $6.4M | 1.09% | 158,500 | SH |
| 33 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $6.3M | 1.08% | 85,311 | SH |
| 34 | STRUCTURE THERAPEUTICS INC Put | GPCR | 86366E106 | $6.1M | 1.05% | 127,500 | SH |
| 35 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $5.8M | 0.99% | 193,189 | SH |
| 36 | ELI LILLY & CO | LLY | 532457108 | $5.5M | 0.94% | 6,000 | SH |
| 37 | ABBVIE INC | ABBV | 00287Y109 | $5.2M | 0.89% | 24,058 | SH |
| 38 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $5.1M | 0.88% | 238,142 | SH |
| 39 | CRISPR THERAPEUTICS AG Call | CRSP | H17182108 | $5.1M | 0.86% | 106,300 | SH |
| 40 | UNIQURE NV Put | QURE | N90064101 | $4.9M | 0.83% | 299,000 | SH |
| 41 | CORBUS PHARMACEUTICALS HLDGS | CRBP | 21833P301 | $4.1M | 0.70% | 439,957 | SH |
| 42 | UNIQURE NV Call | QURE | N90064101 | $4.1M | 0.70% | 250,000 | SH |
| 43 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $3.6M | 0.61% | 244,811 | SH |
| 44 | ZYMEWORKS INC | ZYME | 98985Y108 | $3.6M | 0.61% | 142,132 | SH |
| 45 | REPLIMUNE GROUP INC Put | REPL | 76029N106 | $3.5M | 0.60% | 459,900 | SH |
| 46 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $3.5M | 0.59% | 72,234 | SH |
| 47 | CYTOKINETICS INC Call | CYTK | 23282W605 | $3.3M | 0.56% | 50,000 | SH |
| 48 | VAXCYTE INC Call | PCVX | 92243G108 | $3.1M | 0.53% | 53,100 | SH |
| 49 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $3.1M | 0.52% | 187,307 | SH |
| 50 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $2.9M | 0.49% | 179,738 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $587.7M | 144 | 0001892688-26-000076 |
| 2025-12-31 | 2026-02-17 | $580.5M | 145 | 0001892688-26-000036 |
| 2025-09-30 | 2025-11-14 | $391.0M | 130 | 0001892688-25-000193 |